Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL9068838 | 0.84 | EPAS1 (0.32) | EPAS1ALDH1A1 | |
| SCHEMBL8193143 | 0.84 | EPAS1 (0.32) | EPAS1ALDH1A1 | |
| SCHEMBL20121932 | 0.83 | CXCR4 (0.31) | EPAS1ALDH1A1CXCR4SMN1; SMN2 | |
| SCHEMBL19608324 | 0.82 | ALDH1A1 (0.41) | EPAS1ALDH1A1 | |
| SCHEMBL2931996 | 0.81 | EPAS1 (0.33) | EPAS1ALDH1A1 | |
| SCHEMBL28119029 | 0.81 | EPAS1 (0.33) | EPAS1ALDH1A1 | |
| SCHEMBL16877827 | 0.80 | L3MBTL1 (0.36) | — | |
| SCHEMBL8235477 | 0.79 | L3MBTL1 (0.39) | EPHX1ALDH1A1CXCR4SMN1; SMN2 | |
| SCHEMBL4069679 | 0.79 | MBTD1 (0.32) | — | |
| SCHEMBL17733612 | 0.79 | EPAS1 (0.32) | EPAS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | claimed |
| EP-2328896-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | claimed |
| EP-2318407-B1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | claimed |
| CN-102131808-A | Pyrazolopyridine kinase inhibitors | VERTEX PHARMA | 2011-07-20 | — | — | CN | claimed |
| CN-102131809-A | Tricyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMA | 2011-07-20 | — | — | CN | claimed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | claimed |
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | disclosed |
| CN-103755710-A | 2,5-diazabicyclo heptane compound and application thereof | UNIV KUNMING SCIENCE & TECHNOLOGY | 2014-04-30 | — | — | CN | disclosed |
| CN-103755710-A | 2,5-diazabicyclo heptane compound and application thereof | UNIV KUNMING SCIENCE & TECHNOLOGY | 2014-04-30 | — | — | CN | disclosed |
| CN-101426774-B | Azolecarboxamide derivative | ASTELLAS PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-102131809-A | Tricyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMA | 2011-07-20 | — | — | CN | disclosed |
| CN-102131808-A | Pyrazolopyridine kinase inhibitors | VERTEX PHARMA | 2011-07-20 | — | — | CN | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| CN-101426774-A | Azolecarboxamide derivative | ASTELLAS PHARMA INC (JP) | 2009-05-06 | — | — | CN | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | EPHX1 2942/4885EPAS1 3161/4885ALDH1A1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.